Laisa Ximena Contreras-Aguilar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laisa Ximena Contreras-Aguilar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alin García-Miranda
Laboratorio Internacional EPIGEN-BUAP, Centro de Química Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla C.P. 72570, Mexico
1 shared publication - Andrés Eliú Castell-Rodríguez
Department of Cell and Tissue Biology, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), CP 04510, Mexico City, Mexico, Mexico
1 shared publication - César Beato-López
Departamento de Biología Celular y Tisular, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México C.P. 04510, Mexico
1 shared publication - Erick Francisco Sánchez Ortega
Departamento de Biología Celular y Tisular, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México C.P. 04510, Mexico
1 shared publication - Gabriela Piñón-Zárate
Laboratory of Immunotherapy and Tissue Engineering, Department of Cellular and Tissue Biology, Faculty of Medicine, National Autonomous University of Mexico, Av. Universidad 3000, Copilco Universidad, Coyoacán, Ciudad de México 04510, Mexico
1 shared publication - Jorge Esteban Miranda Calderón
Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Calzada del Hueso 1100, Colonia Villa Quietud, Alcaldía Coyoacán, Ciudad de México C.P. 04960, Mexico
1 shared publication
Latest Publications
- Open Access
- 7 October 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (10) , 507
Release, Cytocompatibility, and In Vivo Biocompatibility of WJ-MSC-Supernatant-Loaded PLGA/NMP In Situ-Forming Implants
(1) Background: Modern pharmacology and regenerative medicine seek effective, safe drug delivery systems that allow for the controlled and sustained release of active ingredients; in situ forming implants (ISFIs) represent one such option. Systems based on poly(lactic-co-glycolic acid) (PLGA) and the solvent N-methyl-2-pyrrolidone (NMP) offer a safe, biodegradable, and non-invasive alternative. (2) Methods: ISFIs were prepared using NMP and PLGA at 50:50 and 85:15 ratios, combined with the supernatant obtained from umbilical cord Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs). Cellular utility, cytotoxicity, cell proliferation, and in vivo biocompatibility were evaluated using Annexin, 7AAD, Calcein, and PrestoBlue assays, as well as a murine model. Statiscal significance was determined using one way ANOVA followed by Tukey’s post hoc test for multiple comparisons, with the significance level at p < 0.05. (3) Results: Differences in cumulative release profile were observed between the PLGA/NMP 50:50 and 85:15 formulations. PLGA 50:50 exhibited higher early and cumulative release of WJ-MSC-supernatant-derived material, whereas PLGA 85:15 showed a slower and more sustained release profile. (4) Conclusions: Cell-free therapy delivered via PLGA 50:50/NMP ISFIs, incorporating associated immunomodulatory factors as supernatant’s WJ-MSCs, is suitable for an effective controlled-release system.
- 7 October 2026
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 17 (10) , 507
Open AccessRelease, Cytocompatibility, and In Vivo Biocompatibility of WJ-MSC-Supernatant-Loaded PLGA/NMP In Situ-Forming Implants
(1) Background: Modern pharmacology and regenerative medicine seek effective, safe drug delivery systems that allow for the controlled and sustained release of active ingredients; in situ forming implants (ISFIs) represent one such option. Systems based on poly(lactic-co-glycolic acid) (PLGA) and the solvent N-methyl-2-pyrrolidone (NMP) offer a safe, biodegradable, and non-invasive alternative. (2) Methods: ISFIs were prepared using NMP and PLGA at 50:50 and 85:15 ratios, combined with the supernatant obtained from umbilical cord Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs). Cellular utility, cytotoxicity, cell proliferation, and in vivo biocompatibility were evaluated using Annexin, 7AAD, Calcein, and PrestoBlue assays, as well as a murine model. Statiscal significance was determined using one way ANOVA followed by Tukey’s post hoc test for multiple comparisons, with the significance level at p < 0.05. (3) Results: Differences in cumulative release profile were observed between the PLGA/NMP 50:50 and 85:15 formulations. PLGA 50:50 exhibited higher early and cumulative release of WJ-MSC-supernatant-derived material, whereas PLGA 85:15 showed a slower and more sustained release profile. (4) Conclusions: Cell-free therapy delivered via PLGA 50:50/NMP ISFIs, incorporating associated immunomodulatory factors as supernatant’s WJ-MSCs, is suitable for an effective controlled-release system.